FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Emily Blood

Research Profile

Disorders

Concepts & Ideas

Procedures

Physiology

Disease Progression

Chemicals & Drugs

Anatomy

Phenomena

Recurrence

Co-author Network

Publications

TOP 3
Shaji Kumar; L Zhang; Angela Dispenzieri; Scott A Van Wier; Jerry A Katzmann; M Snyder; Emily Blood; R DeGoey; Kim Henderson; Robert A Kyle; Arthur R Bradwell; Philip R Greipp; S Vincent Rajkumar; Rafael Fonseca
Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma.
Martha Q Lacy; Susanna Jacobus; Emily Blood; Neil E Kay; S Vincent Rajkumar; Philip R Greipp
Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group.
Ann H Partridge; Jeffrey P Winer; Mehra Golshan; Jennifer Bellon; Emily Blood; Elizabeth Dees; Ebonie Sampson; Karen M Emmons; Eric P Winer
Perceptions and management approaches of physicians who care for women with ductal carcinoma in situ.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Emily Blood (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: Shaji Kumar; L Zhang; Angela Dispenzieri; Scott A Van Wier; Jerry A Katzmann; M Snyder; Emily Blood; R DeGoey; Kim Henderson; Robert A Kyle; Arthur R Bradwell; Philip R Greipp; S Vincent Rajkumar; Rafael Fonseca
Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma.
Leukemia 2010;24(8):1498-505.
2009: Martha Q Lacy; Susanna Jacobus; Emily Blood; Neil E Kay; S Vincent Rajkumar; Philip R Greipp
Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group.
Leukemia research 2009;33(11):1485-9.
2008: Ann H Partridge; Jeffrey P Winer; Mehra Golshan; Jennifer Bellon; Emily Blood; Elizabeth Dees; Ebonie Sampson; Karen M Emmons; Eric P Winer
Perceptions and management approaches of physicians who care for women with ductal carcinoma in situ.
Clinical breast cancer 2008;8(3):275-80.
2008: Angela Dispenzieri; Lijun Zhang; Jerry A Katzmann; Melissa Snyder; Emily Blood; Roberta Degoey; Kim Henderson; Robert A Kyle; Martin M Oken; Arthur R Bradwell; Philip R Greipp
Appraisal of immunoglobulin free light chain as a marker of response.
Blood 2008;111(10):4908-15.
2008: Ann H Partridge; Kristie Adloff; Emily Blood; Elizabeth Dees; Carolyn Kaelin; Mehra Golshan; Jennifer A Ligibel; Janet de Moor; Jane C Weeks; Karen M Emmons; Eric P Winer
Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study.
Journal of the National Cancer Institute 2008;100(4):243-51.
2007: Jeffrey Peppercorn; Emily Blood; Eric P Winer; Ann H Partridge
Association between pharmaceutical involvement and outcomes in breast cancer clinical trials.
Cancer 2007;109(7):1239-46.
2007: Wee J Chng; Tammy Price-Troska; N Gonzalez-Paz; Scott A Van Wier; S Jacobus; Emily Blood; K Henderson; Martin M Oken; Brian Van Ness; Philip R Greipp; S Vincent Rajkumar; Rafael Fonseca
Clinical significance of TP53 mutation in myeloma.
Leukemia 2007;21(3):582-4.
2007: Natalia Gonzalez-Paz; Wee J Chng; Rebecca F McClure; Emily Blood; Martin M Oken; Brian Van Ness; C David James; Paul J Kurtin; Kim Henderson; Gregory J Ahmann; Morie A Gertz; Martha Lacy; Angela Dispenzieri; Philip R Greipp; Rafael Fonseca
Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications.
Blood 2007;109(3):1228-32.
2006: Paul G Richardson; Emily Blood; Constantine S Mitsiades; Sundar Jagannath; Steven R Zeldenrust; Melissa Alsina; Robert Schlossman; S Vincent Rajkumar; K Raman Desikan; Teru Hideshima; Nikhil C Munshi; Kathleen Kelly-Colson; Deborah Doss; Mary L McKenney; Svetlana Gorelik; Diane Warren; Andrea Freeman; Rebecca Rich; Anfang Wu; Marta Olesnyckyj; Kenton Wride; William S Dalton; Jerome B Zeldis; Robert Knight; Edie Weller; Kenneth C Anderson
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Blood 2006;108(10):3458-64.
2006: Wee J Chng; Rafael Santana-Dávila; Scott A Van Wier; Gregory J Ahmann; Syed M Jalal; P Leif Bergsagel; Marta Chesi; Mike C Trendle; S Jacobus; Emily Blood; Martin M Oken; K Henderson; Robert A Kyle; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Philip R Greipp; Rafael Fonseca
Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations.
Leukemia 2006;20(5):807-13.
2006: Wee J Chng; Jerry M Winkler; Philip R Greipp; Syed M Jalal; P Leif Bergsagel; Marta Chesi; Mike C Trendle; Gregory J Ahmann; Kim Henderson; Emily Blood; Martin M Oken; A Hulbert; Scott A Van Wier; Rafael Santana-Dávila; Robert A Kyle; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Rafael Fonseca
Ploidy status rarely changes in myeloma patients at disease progression.
Leukemia research 2006;30(3):266-71.
2006: William R Friedenberg; Montserrat Rue; Emily Blood; William S Dalton; Chaim Shustik; Richard A Larson; Pieter Sonneveld; Philip R Greipp
Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group.
Cancer 2006;106(4):830-8.
2005: Wee J Chng; Scott A Van Wier; Gregory J Ahmann; Jerry M Winkler; Syed M Jalal; P Leif Bergsagel; Marta Chesi; Mike C Trendle; Martin M Oken; Emily Blood; Kim Henderson; Rafael Santana-Dávila; Robert A Kyle; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Philip R Greipp; Rafael Fonseca
A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS.
Blood 2005;106(6):2156-61.
2005: Sharon Galper; Emily Blood; Rebecca Gelman; Anthony Abner; Abram Recht; Anita Kohli; Julia S Wong; Darrell Smith; Jennifer Bellon; James Connolly; Stuart J Schnitt; Eric P Winer; Barbara Silver; Jay R Harris
Prognosis after local recurrence after conservative surgery and radiation for early-stage breast cancer.
International journal of radiation oncology, biology, physics 2005;61(2):348-57.
2004: Irene M Ghobrial; Rafael Fonseca; Philip R Greipp; Emily Blood; Montserrat Rue; David H Vesole; Morie A Gertz
Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study.
Cancer 2004;101(11):2593-8.
2004: Morie A Gertz; Montserrat Rue; Emily Blood; Lynne S Kaminer; David H Vesole; Philip R Greipp
Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98).
Leukemia & lymphoma 2004;45(10):2047-55.
2004: Paul Richardson; Robert Schlossman; Sundar Jagannath; Melissa Alsina; Raman Desikan; Emily Blood; Edie Weller; Constantine S Mitsiades; Teru Hideshima; Faith Davies; Deborah Doss; Andrea Freeman; Joan Bosch; John Patin; Robert Knight; Jerome B Zeldis; William Dalton; Kenneth C Anderson
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.
Mayo Clinic proceedings. Mayo Clinic 2004;79(7):875-82.
2004: Morie A Gertz; Emily Blood; David H Vesole; Rafat Abonour; H M Lazarus; Philip R Greipp
A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group Study.
Bone marrow transplantation 2004;34(2):149-54.
2004: Ann H Partridge; Nadia Hackett; Emily Blood; Rebecca Gelman; Steven Joffe; Susan Bauer-Wu; Katherine Knudsen; Karen M Emmons; Deborah Collyar; Richard L Schilsky; Eric P Winer
Oncology physician and nurse practices and attitudes regarding offering clinical trial results to study participants.
Journal of the National Cancer Institute 2004;96(8):629-32.
2003: Rafael Fonseca; Carina S Debes-Marun; Elisa Beth Picken; Gordon W Dewald; Sandra C Bryant; Jerry M Winkler; Emily Blood; Martin M Oken; Rafael Santana-Dávila; Natalia González-Paz; Robert A Kyle; Morie A Gertz; Angela Dispenzieri; Martha Q Lacy; Philip R Greipp
The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma.
Blood 2003;102(7):2562-7.
2003: William R Friedenberg; David Graham; Philip R Greipp; Emily Blood; Robert D Winston
The treatment of multiple myeloma with docetaxel (an ECOG study).
Leukemia research 2003;27(8):751-4.
2003: Rafael Fonseca; Emily Blood; Montserrat Rue; David Harrington; Martin M Oken; Robert A Kyle; Gordon W Dewald; Brian Van Ness; Scott A Van Wier; Kimberly J Henderson; Richard J Bailey; Philip R Greipp
Clinical and biologic implications of recurrent genomic aberrations in myeloma.
Blood 2003;101(11):4569-75.
2002: Rafael Fonseca; Emily Blood; Martin M Oken; Robert A Kyle; Gordon W Dewald; Richard J Bailey; Scott A Van Wier; Kimberly J Henderson; James D Hoyer; David Harrington; Neil E Kay; Brian Van Ness; Philip R Greipp
Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.
Blood 2002;99(10):3735-41.
2002: Rafael Fonseca; David Harrington; Martin M Oken; Gordon W Dewald; Richard J Bailey; Scott A Van Wier; Kimberly J Henderson; Emily Blood; S Vincent Rajkumar; Neil E Kay; Brian Van Ness; Philip R Greipp
Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study.
Cancer research 2002;62(3):715-20.